0 (0%)		09-27 09:32
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.85	1-year :	0.93
Resists	First :	0.73	Second :	0.8
Pivot price	0.7
Supports	First :	0.62	Second :	0.52
MAs	MA(5) :	0.69	MA(20) :	0.71
	MA(100) :	0.93	MA(250) :	1.39
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	39.5	D(3) :	36.8
RSI	RSI(14): 49.9
52-week	High :	3.75	Low :	0.51

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BCLI ] has closed below upper band by 45.5%. Bollinger Bands are 68.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.71 - 0.71	0.71 - 0.72
Low:	0.68 - 0.69	0.69 - 0.69
Close:	0.7 - 0.71	0.71 - 0.72

Thu, 25 Sep 2025
Cell Therapeutics Inc. Securities Lawsuit Investigation - Claim Depot

Mon, 22 Sep 2025
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Beh - GlobeNewswire

Fri, 15 Aug 2025
BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS… - Yahoo Finance

Thu, 14 Aug 2025
BrainStorm's ALS Drug Shows 100% 5-Year Survival Rate as FDA Clears New Phase 3b Trial - Stock Titan

Thu, 14 Aug 2025
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Thu, 17 Jul 2025
BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	10 (M)
Shares Float	9 (M)
Held by Insiders	11.9 (%)
Held by Institutions	3.7 (%)
Shares Short	604 (K)
Shares Short P.Month	537 (K)

EPS	-1.74
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.61
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-180.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.13
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.42
PEG Ratio	0
Price to Book value	-1.19
Price to Sales	0
Price to Cash Flow	-0.78

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.